2026-04-23 16:00:26 UTC / 路透社
作者：特雷弗·哈尼克特、斯里帕尔纳·罗伊、艾哈迈德·阿布勒内因
2026年4月23日 16:00 UTC 更新于1分钟前
节点运行失败
[1/2]美国商务部长霍华德·卢特尼克、美国卫生与公众服务部（HHS）部长小罗伯特·F·肯尼迪、美国医疗保险和医疗补助服务中心主任穆罕默德·奥兹、再生元制药首席科学官乔治·D·扬科普洛斯、医疗保险中心主任克里斯·克朗普… 购买授权许可，打开新标签页查看更多
华盛顿4月23日路透电——美国总统唐纳德·特朗普周四宣布与再生元制药（REGN.O）达成药品定价协议，敲定了与本届政府谈判的17家大型制药公司的最终协议。
包括辉瑞（PFE.N）、礼来（LLY.N）和安进（AMGN.O）在内的企业已同意下调其针对政府低收入人群医疗救助计划（Medicaid）的药品价格，以及特朗普政府为将美国药品成本与其他富裕国家看齐而针对现金支付患者的药品价格。
通过路透社健康周刊通讯，及时了解最新医学突破和医疗趋势。点击此处订阅。
广告 · 滚动继续
作为换取三年药品进口关税豁免的条件，制药商承诺采用“最惠国”定价模式，通过一个名为TrumpRx.gov的新政府平台直接向消费者销售药品，并承诺在美国境内投资数十亿美元。
“我很高兴地宣布，全球最受尊敬的制药公司之一——坦白说，我对它非常了解——再生元，已经同意以大幅折扣的最惠国价格提供其处方药，”特朗普在椭圆形办公室说道。
再生元制药股价当日收盘上涨2.6%。
广告 · 滚动继续
目前美国患者在处方药上的花费遥遥领先其他国家，通常是其他发达国家的近三倍。特朗普一直向制药商施压，要求其将药品价格降至其他国家患者支付的水平。
特朗普在椭圆形办公室的活动中表示，再生元已同意下调其现有和未来药物针对医疗救助计划的定价。
该公司的基因疗法Otarmeni已获批用于治疗一种罕见的儿童听力损失。
特朗普称，该疗法将在美国免费提供。他还表示，该制药商同意将其胆固醇药物Praluent的售价从537美元降至225美元，并将该药物上架TrumpRx平台。
参与谈判的核心人物、美国卫生与公众服务部首席顾问克里斯·克朗普表示，这17家公司占据了美国品牌处方药市场86%的份额。不过根据美国食品药品监督管理局的数据，美国销售的药品中超过90%为仿制药。
斯里帕尔纳·罗伊在班加罗尔报道；特雷弗·哈尼克特与艾哈迈德·阿布勒内因在华盛顿报道；迈克尔·厄尔曼在新泽西补充报道；苏珊·希维与马朱·塞缪尔编辑
我们的准则：汤森路透信任原则。
Trump announces drug pricing deal with Regeneron
2026-04-23 16:00:26 UTC / Reuters
By Trevor Hunnicutt, Sriparna Roy and Ahmed Aboulenein
April 23, 2026 4:00 PM UTC Updated 1 min ago
节点运行失败
[1/2]U.S. Secretary of Commerce Howard Lutnick, U.S. Health and Human Services (HHS) Secretary Robert F. Kennedy Jr., Administrator for the Centers for Medicare & Medicaid Services Mehmet Oz, Chief Scientific Officer at Regeneron George D. Yancopoulos, Director of the Center for Medicare Chris Klomp… Purchase Licensing Rights, opens new tabRead more
WASHINGTON, April 23 (Reuters) – President Donald Trump announced a drug pricing deal with Regeneron Pharmaceuticals (REGN.O) on Thursday, wrapping up the final agreement among the 17 large pharmaceutical companies that negotiated deals with his administration.
Companies including Pfizer (PFE.N), Eli Lilly (LLY.N) and Amgen (AMGN.O) have agreed to slash prices of their medicines for the government’s Medicaid program for low-income people and for cash payers in Trump’s bid to align U.S. costs with those in other wealthy nations.
Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here.
Advertisement · Scroll to continue
In exchange for three-year exemptions from tariffs on drug imports, the drugmakers have committed to “most-favored nation” pricing, to sell drugs directly to consumers through a new government platform called TrumpRx.gov, and pledged billions of dollars in U.S. investments.
“I’m thrilled to announce that one of the most respected pharmaceutical companies anywhere in the world, frankly, I know it very well is Regeneron, and it’s agreed to offer their prescription medications at heavily discounted most favored nation prices,” Trump said in the Oval Office.
Regeneron shares ended up 2.6% on the day.
Advertisement · Scroll to continue
U.S. patients currently pay by far the most for prescription medicines, often nearly three times more than other developed nations. Trump has been pressuring drugmakers to lower their prices to what patients pay elsewhere.
Regeneron has agreed to reduce Medicaid prices for its current and future medications, Trump said at the Oval Office event.
The company has also received approval for its gene therapy Otarmeni for children with a rare type of hearing loss.
The therapy will be made available for free in the U.S., Trump said. The drugmaker has also agreed to sell its cholesterol drug Praluent for $225, he said, down from $537, and will list it on TrumpRx.
The 17 companies account for 86% of the branded pharmaceutical drug market in the United States, said Chris Klomp, chief counselor of the Department of Health and Human Services, who played a leading role in the negotiations. However, more than 90% of medicines sold in the U.S. are generics, according to the U.S. Food and Drug Administration.
Reporting by Sriparna Roy in Bengaluru; Trevor Hunnicutt and Ahmed Aboulenein in Washington; Additional reporting by Michael Erman in New Jersey; Editing by Susan Heavey and Maju Samuel
Our Standards: The Thomson Reuters Trust Principles.
发表回复